{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:46:00Z","timestamp":1793907960790,"version":"4.8.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"23","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education in Poland","award":["DWD\/4\/16\/2020"],"award-info":[{"award-number":["DWD\/4\/16\/2020"]}]},{"name":"Mabion S.A"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/17576180.2025.2601860","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:18:57Z","timestamp":1765876737000},"page":"1569-1580","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Addressing nonspecific interactions in a Gyrolab anti-drug antibody (ADA) assay: a case study on method optimization to improve repeatability"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-7336","authenticated-orcid":false,"given":"Eliza","family":"K\u0119sy-Siwik","sequence":"first","affiliation":[{"name":"Mabion S.A","place":["Konstantyn\u00f3w \u0141\u00f3dzki, Poland"]},{"name":"Medical University of Lodz","place":["\u0141\u00f3d\u017a, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1685-5241","authenticated-orcid":false,"given":"John","family":"Chappell","sequence":"additional","affiliation":[{"name":"Gyros Protein Technologies AB","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Jaros","sequence":"additional","affiliation":[{"name":"Mabion S.A","place":["Konstantyn\u00f3w \u0141\u00f3dzki, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Urbaniak","sequence":"additional","affiliation":[{"name":"Medical University of Lodz","place":["\u0141\u00f3d\u017a, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-2046","authenticated-orcid":false,"given":"Agata","family":"Sakowicz","sequence":"additional","affiliation":[{"name":"Medical University of Lodz","place":["\u0141\u00f3d\u017a, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"e_1_3_8_3_1","unstructured":"European Medicines Agency. European public assessment report for MabThera [Internet]. Amsterdam The Netherlands; 2025 [cited 2025 Oct 15]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.06.002"},{"key":"e_1_3_8_5_1","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): guideline on immunogenicity assessment of therapeutic proteins. EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1 [Internet]. London United Kingdom; 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155627"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151951"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2903-1_9"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-0006-z"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2012.03.001"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2021-0018"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0386-y"},{"key":"e_1_3_8_14_1","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER): Considerations in demonstrating interchangeability with a reference product (Guidance for Industry) [Internet]. Washington DC; 2019. Available from: https:\/\/www.fda.gov\/media\/124907\/download"},{"key":"e_1_3_8_15_1","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER): Clinical pharmacology data to support a demonstration of biosimilarity to a reference product (Guidance for Industry) [Internet]. Washington DC; 2016. Available from: https:\/\/www.fda.gov\/media\/88622\/download"},{"key":"e_1_3_8_16_1","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER): scientific considerations in demonstrating biosimilarity to a reference product (Guidance for Industry) [Internet]. Washington DC; 2015. Available from: https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"e_1_3_8_17_1","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA\/CHMP\/BMWP\/42832\/2005 Rev1 [Internet]. London United Kingdom; 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.020"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00540-8"},{"key":"e_1_3_8_20_1","first-page":"105","article-title":"Interferences in immunoassay","volume":"25","author":"Tate J","year":"2004","unstructured":"Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev. 2004;25:105\u2013120.","journal-title":"Clin Biochem Rev"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.705038"},{"key":"e_1_3_8_22_1","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human (CHMP): ICH guideline M10 on bioanalytical method validation and study sample analysis. EMA\/CHMP\/ICH\/172948\/2019 [Internet]. Amsterdam The Netherlands; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib11020024"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00759-1"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2017.12.011"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2010.03.036"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201600299"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphc.202000935"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ange.201907298"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/002215540305101214"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00373"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2007.10.003"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41529-025-00552-3"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00866a011"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0cp00253d"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2025.2601860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:24:44Z","timestamp":1770020684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17576180.2025.2601860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/17576180.2025.2601860"],"URL":"https:\/\/doi.org\/10.1080\/17576180.2025.2601860","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}